Brief Title: Aerobic Training on Cerebrovascular Function, Cognition and Gait in Parkinson's Disease
NCT07478146, Not applicable, Recruiting, Raphael Mendes Ritti Dias
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Brief Title: Aerobic Training on Cerebrovascular Function, Cognition and Gait in Parkinson's Disease | ClinicalTrials.gov |
| NCT number | NCT07478146 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 40 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Raphael Mendes Ritti Dias | ClinicalTrials.gov |
| Conditions | PARKINSON DISEASE (Disorder) | ClinicalTrials.gov |
| Interventions | Aerobic training, Usual Care | ClinicalTrials.gov |
| First posted | 2026-03-17 | ClinicalTrials.gov |
| Last updated | 2026-04-13 | ClinicalTrials.gov |
Registered outcomes 34
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Cerebrovascular Reactivity | Baseline and 12 weeks | Breath-holding index (dimensionless) assessed by transcranial Doppler | ClinicalTrials.gov |
| Primary | Change in Neurovascular Coupling at 12 Weeks. | Baseline and 12 weeks | Measured by relative (%) changes in middle cerebral artery blood flow velocity during standardized cognitive tasks (Stroop Color-Word Test, Trail Making Test A and B, and silent reading protocol) using transcranial Doppler ultrasound. | ClinicalTrials.gov |
| Primary | Change in Dynamic Cerebral Autoregulation | Baseline and 12 weeks | Transfer function gain and phase (0.02-0.4 Hz frequency bands). | ClinicalTrials.gov |
| Primary | Change in Acute Cerebral Blood Flow Response to Exercise | Baseline and 12 weeks | Change in middle cerebral artery velocity during 6-minute aerobic bout. | ClinicalTrials.gov |
| Secondary | Change in Brachial Artery Endothelial Function | Baseline and 12 weeks | Flow-mediated dilation (FMD, %) of the brachial artery assessed by high-resolution vascular ultrasound according to current guidelines. | ClinicalTrials.gov |
| Secondary | Change in Brachial Artery Baseline Diameter | Baseline and 12 weeks | Resting brachial artery diameter (mm) measured by vascular ultrasound | ClinicalTrials.gov |
| Secondary | Change in Carotid Intima-Media Thickness | Baseline and 12 weeks | Common carotid artery intima-media thickness (mm) assessed by B-mode ultrasound. | ClinicalTrials.gov |
| Secondary | Change in Resting Blood Pressure | Baseline and 12 weeks | Systolic and diastolic blood pressure (mmHg). | ClinicalTrials.gov |
| Secondary | Change in Resting Heart Rate | Baseline and 12 weeks | Heart rate (beats per minute). | ClinicalTrials.gov |
| Secondary | Change in SDNN | Baseline and 12 weeks | SDNN derived from beat-to-beat recordings at rest. | ClinicalTrials.gov |
| Secondary | Change in Low Frequency Power | Baseline and 12 weeks | Low-frequency power (ms²) derived from spectral analysis. | ClinicalTrials.gov |
| Secondary | Change in Cognitive Function | Baseline and 12 weeks | Assessed with Montreal Cognitive Assessment that provides a score | ClinicalTrials.gov |
| Secondary | Change in Executive Function and Attention | Baseline and 12 weeks | Assessed with Trail Making Test Part A and Part B (time to completion, seconds). | ClinicalTrials.gov |
| Secondary | Change in Non-Motor Symptoms | Baseline and 12 weeks | Assessed with Non-Motor Symptoms Scale that provides a score. Higher scores indicate greater symptom burden. | ClinicalTrials.gov |
| Secondary | Change in Parkinson Disease Severity | Baseline and 12 weeks | Assessed with the Unified Parkinson's Disease Rating Scale (UPDRS total score). | ClinicalTrials.gov |
| Secondary | Change in Anxiety Severity | Baseline and 12 weeks | Assessed with the Parkinson Anxiety Scale total score (0-48). Higher scores indicate greater anxiety severity. | ClinicalTrials.gov |
| Secondary | Change in Depressive Symptoms | Baseline and 12 weeks | Assessed with Geriatric Depression Scale total score (0-15). Higher scores indicate greater depressive symptom severity. | ClinicalTrials.gov |
| Secondary | Change in Apathy | Baseline and 12 weeks | Assessed with Apathy Inventory total score (0-12). Higher scores indicate greater apathy. | ClinicalTrials.gov |
| Secondary | Change in Fatigue | Baseline and 12 weeks | Parkinson Fatigue Scale total score (range: 16-80). Higher scores indicate greater fatigue severity. | ClinicalTrials.gov |
| Secondary | Change in Sleep Quality | Baseline and 12 weeks | Assessed with Parkinson's Disease Sleep Scale total score (0-150). Lower scores indicate worse sleep quality. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)